EpiVax has been granted a patent for compositions containing regulatory T cell epitopes, including polypeptides from SEQ NOS: 1-124. The patent also covers methods of producing and using these compositions to induce regulatory T-cells and suppress immune responses in subjects. GlobalData’s report on EpiVax gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights EpiVax Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on EpiVax, Peptide pharmacophores was a key innovation area identified from patents. EpiVax's grant share as of February 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.

Patent granted for t-cell epitope composition to suppress immune response

Source: United States Patent and Trademark Office (USPTO). Credit: EpiVax Inc

A recently granted patent (Publication Number: US11911414B2) discloses a method for inducing regulatory T-cells to suppress immune responses in a subject. The method involves administering a T-cell epitope composition containing isolated T-cell epitope polypeptides, with at least one polypeptide having a specific amino acid sequence. Additionally, the composition may include other isolated T-cell epitope polypeptides with different amino acid sequences, antigens, and/or allergens to enhance its therapeutic effectiveness.

The patent claims highlight the potential of the T-cell epitope composition to mediate immune suppressive effects through natural regulatory T cells or adaptive regulatory T-cells. Furthermore, the composition is designed to suppress effector T-cell responses, including cytokine secretion, helper T-cell responses, and B-cell responses. By targeting specific T-cell epitopes, this method offers a promising approach to modulate immune responses in subjects, potentially leading to new therapeutic strategies for various conditions related to immune dysregulation.

To know more about GlobalData’s detailed insights on EpiVax, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies